Timing of Adjuvant Chemotherapy and Breast Cancer Prognosis
Author Information
Author(s): C. Alliot
Primary Institution: General Hospital of Annemasse
Hypothesis
Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer?
Conclusion
The timing of the first cycle of adjuvant chemotherapy does not significantly affect the prognosis in early breast cancer patients.
Supporting Evidence
- No significant benefit was observed in patients who had received the first cycle within 21 days after surgery.
- The study included a large cohort of 7501 patients, providing a substantial data set for analysis.
- The analysis indicated that the delay in starting chemotherapy was arbitrary and not supported by biological evidence.
Takeaway
This study looked at when breast cancer patients should start chemotherapy after surgery, and it found that starting it sooner doesn't help them more than waiting a little longer.
Methodology
The study reviewed data from the Danish Breast Cancer Cooperative Group, analyzing outcomes based on the timing of chemotherapy initiation post-surgery.
Potential Biases
The study may have selection bias due to the historical treatment criteria and the unknown estrogen-receptor status in many patients.
Limitations
Most patients were treated before 1998, and many had large tumors, which may not represent the current patient population.
Participant Demographics
Patients included were those with early breast cancer who received adjuvant chemotherapy, primarily treated before 1998.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website